Van ECK Associates Corp Buys 136,519 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Posted by Stanley Muller on Jun 13th, 2026

Van ECK Associates Corp lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 3.9% in the 4th quarter, HoldingsChannel reports. The firm owned 3,613,425 shares of the medical equipment provider’s stock after buying an additional 136,519 shares during the quarter. Van ECK Associates Corp’s holdings in Zimmer Biomet were worth $324,920,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Flagship Harbor Advisors LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth about $32,000. Grove Bank & Trust lifted its position in shares of Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 328 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter worth about $37,000. Basepoint Wealth LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth about $38,000. Finally, JFS Wealth Advisors LLC lifted its position in shares of Zimmer Biomet by 306.7% in the 3rd quarter. JFS Wealth Advisors LLC now owns 427 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 322 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Trading Up 1.6%

ZBH opened at $88.54 on Friday. The stock has a market cap of $17.13 billion, a PE ratio of 23.00, a PEG ratio of 2.01 and a beta of 0.47. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $87.56 and a 200-day moving average of $90.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the company earned $1.81 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Citizens Jmp lowered their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research note on Wednesday, April 29th. JPMorgan Chase & Co. lowered their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lowered their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Finally, BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $102.70.

Get Our Latest Report on ZBH

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.